AGIO
AgiosFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive clinical readouts or a value-accretive partnership that materially de-risks programs and meaningfully extends runway could push shares toward the bull target (~+40% vs anchor).
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Clinical trial failure or safety signal
Momentum
35
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.08 · Bull $5.19 · Bear $2.60
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-10 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $38.88
Why
Momentum35 · Δ7d +12.6
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
35
34% active weight
Current posture
7d trendImproving
Δ7d
+12.6
Δ21d
+30.2
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 35.2 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.58B
Beta
0.91
Shares Out
58.31M
P/E (TTM)
3.8
P/S (TTM)
35.74
P/FCF (TTM) · Derived
-3.76
Rev YoY
+43.7%
EPS YoY
-111.0%
Gross Margin
+87.2%
Op Margin
-1061.8%
Net Debt
-$893.71M
Current Ratio
13.82
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology